Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Non-Current Assets (2020 - 2025)

Historic Non-Current Assets for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $68.0 million.

  • Apellis Pharmaceuticals' Non-Current Assets rose 11.48% to $68.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $309.5 million, marking a year-over-year increase of 9918.59%. This contributed to the annual value of $96.1 million for FY2024, which is 32902.36% up from last year.
  • According to the latest figures from Q3 2025, Apellis Pharmaceuticals' Non-Current Assets is $68.0 million, which was up 11.48% from $65.8 million recorded in Q2 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Non-Current Assets peaked at $96.1 million during Q4 2024, and registered a low of $20.5 million during Q1 2024.
  • For the 5-year period, Apellis Pharmaceuticals' Non-Current Assets averaged around $46.8 million, with its median value being $42.5 million (2022).
  • As far as peak fluctuations go, Apellis Pharmaceuticals' Non-Current Assets tumbled by 4762.79% in 2023, and later skyrocketed by 32902.36% in 2024.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' Non-Current Assets stood at $57.7 million in 2021, then dropped by 29.5% to $40.7 million in 2022, then tumbled by 44.96% to $22.4 million in 2023, then skyrocketed by 329.02% to $96.1 million in 2024, then fell by 29.19% to $68.0 million in 2025.
  • Its last three reported values are $68.0 million in Q3 2025, $65.8 million for Q2 2025, and $79.6 million during Q1 2025.